Shares of French pharmaceutical group Sanofi fell 4% on Monday after it flagged another delay to a U.S. regulatory decision ...
A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of ...
Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t ...
Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Ongoing discussions with the FDA regarding nrSPMS application have indicated ...
Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to ...
Tolebrutinib received provisional approval in the United Arab Emirates in July 2025 for non-relapsing secondary progressive ...
Get the latest on major stock moves, including iRobot's bankruptcy and key biotech and software sector updates.
The pan-European STOXX 600 was up 0.4% at 580.35, as of 0808 GMT, remaining within striking distance of an intraday record ...
Dow Jones Top Company Headlines at 3 AM ET: Sanofi Multiple Sclerosis Drug Hit by Double Setback | China ... A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial ...
In the big picture, matched sibling donor transplants remain the standard of care, Boelens said. But gene therapy is ...
The ECB meets on Thursday, and is widely expected to hold its key rate at 2% for a fourth straight meeting. Traders will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback